{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:06:04Z","timestamp":1792058764755,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["2020-02653"],"award-info":[{"award-number":["2020-02653"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["2020-02653"],"award-info":[{"award-number":["2020-02653"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Concerns exist that psychostimulants may increase the risk of psychosis, particularly in individuals with a history of psychosis. This study assessed whether psychosis risk increases after initiating psychostimulant or atomoxetine treatment in individuals with prior psychotic events. In this cohort study, we used Swedish population-based register data that contain data on all Swedish residents. We identified adults aged 18\u201364, who had a history of psychosis and initiated psychostimulant or atomoxetine treatment between 2008 and 2021. A within-individual design compared the rate of psychotic events in two 6-month periods before and after treatment initiation. Rate ratios (RR) with 95% confidence intervals (CI) were estimated. Sensitivity analyses were stratified by sex, age groups, and medication classes and also investigated substance-related psychosis as alternative outcome. We identified 3,770 individuals with a history of psychosis that received psychostimulant or atomoxetine prescriptions during the study period. Compared to the period before treatment initiation, the RR for psychotic events in the six months following treatment initiation was 0.95 (95% CI 0.84\u20131.08). Sensitivity analyses, considering only substance-induced psychotic events, or eight-week intervals and subgroup analyses by sex, age groups and separately for individuals receiving either (dex-)methyphenidate or (lis-)dexamphetamine or atomoxetine or (ar-)modafinil showed consistent results. Contrary to concerns, psychostimulant or atomoxetine treatment was not associated with an increased risk of psychotic events in adults with a history of psychosis. These findings may inform clinicians considering psychostimulant prescriptions in this population.<\/jats:p>","DOI":"10.1038\/s41398-026-03998-4","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T22:26:32Z","timestamp":1774995992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prescription psychostimulants, atomoxetine and the risk of psychosis in adults with history of psychosis: a population-based cohort study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5962-019X","authenticated-orcid":false,"given":"Patrick","family":"Bach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4355-1967","authenticated-orcid":false,"given":"Johan","family":"Franck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"H\u00e4llgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e4rje","family":"Widing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Gissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Westman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"12","key":"3998_CR1","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00228-016-2125-y","volume":"72","author":"O Karlstad","year":"2016","unstructured":"Karlstad O, Zoega H, Furu K, Bahmanyar S, Martikainen JE, Kieler H, et al. Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries. Eur J Clin Pharmacol. 2016;72(12):1507\u201314.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"3998_CR2","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S2215-0366(18)30293-1","volume":"5","author":"SR Raman","year":"2018","unstructured":"Raman SR, Man KKC, Bahmanyar S, Berard A, Bilder S, Boukhris T, et al. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry. 2018;5(10):824\u201335.","journal-title":"Lancet Psychiatry"},{"key":"3998_CR3","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.2147\/CLEP.S178638","volume":"10","author":"PJ Bjerkeli","year":"2018","unstructured":"Bjerkeli PJ, Vicente RP, Mulinari S, Johnell K, Merlo J. Overuse of methylphenidate: an analysis of Swedish pharmacy dispensing data. Clin Epidemiol. 2018;10:1657\u201365.","journal-title":"Clin Epidemiol"},{"key":"3998_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/BF00216006","volume":"91","author":"J Lieberman","year":"1987","unstructured":"Lieberman J, Kane J, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl). 1987;91:415\u201333.","journal-title":"Psychopharmacology (Berl)"},{"issue":"7","key":"3998_CR5","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1176\/ajp.2006.163.7.1149","volume":"163","author":"RG Ross","year":"2006","unstructured":"Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry. 2006;163(7):1149\u201352.","journal-title":"Am J Psychiatry"},{"key":"3998_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.schres.2020.01.021","volume":"218","author":"E Bj\u00f6rkenstam","year":"2020","unstructured":"Bj\u00f6rkenstam E, Pierce M, Bj\u00f6rkenstam C, Dalman C, Kosidou K. Attention Deficit\/Hyperactivity Disorder and risk for non-affective psychotic disorder: The role of ADHD medication and comorbidity, and sibling comparison. Schizophr Res. 2020;218:124\u201330.","journal-title":"Schizophr Res"},{"issue":"3","key":"3998_CR7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1192\/bjp.185.3.196","volume":"185","author":"C Curran","year":"2004","unstructured":"Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry. 2004;185(3):196\u2013204.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"3998_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jamapsychiatry.2023.5045","volume":"81","author":"G Chai","year":"2024","unstructured":"Chai G, Xu J, Goyal S, Woods C, Ho A, Song J, et al. Trends in Incident Prescriptions for Behavioral Health Medications in the US, 2018-2022. JAMA Psychiatry. 2024;81(4):396\u2013405.","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"3998_CR9","doi-asserted-by":"publisher","first-page":"e2433334","DOI":"10.1001\/jamanetworkopen.2024.33334","volume":"7","author":"A Nagappan","year":"2024","unstructured":"Nagappan A, Miller A, Jain S, Oakes AH. Stimulant, Antidepressant, and Opioid Telehealth Prescription Trends Between 2019 and 2022. JAMA Network Open. 2024;7(9):e2433334.","journal-title":"JAMA Network Open"},{"key":"3998_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.15585\/mmwr.mm7213a1","volume":"72","author":"ML Danielson","year":"2023","unstructured":"Danielson ML. Trends in stimulant prescription fills among commercially insured children and adults\u2014United States, 2016\u20132021. MMWR Morb Mortal Wkly Rep. 2023;72:327\u201332.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"3998_CR11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1542\/peds.2008-0185","volume":"123","author":"AD Mosholder","year":"2009","unstructured":"Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit\/hyperactivity disorder drugs in children. Pediatrics. 2009;123(2):611\u20136.","journal-title":"Pediatrics"},{"issue":"1","key":"3998_CR12","first-page":"52","volume":"6","author":"E Ramstad","year":"2018","unstructured":"Ramstad E, Storeb\u00f8 OJ, Gerner T, Krogh HB, Holmskov M, Magnusson FL, et al. Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention-deficit\/hyperactivity disorder: a Cochrane systematic review with meta-analysis and trial sequential analysis. Scand J Child Adolesc Psychiatry Psychol. 2018;6(1):52.","journal-title":"Scand J Child Adolesc Psychiatry Psychol"},{"issue":"8","key":"3998_CR13","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S2215-0366(19)30189-0","volume":"6","author":"C Hollis","year":"2019","unstructured":"Hollis C, Chen Q, Chang Z, Quinn PD, Viktorin A, Lichtenstein P, et al. Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study. Lancet Psychiatry. 2019;6(8):651\u20138.","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"3998_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1192\/bjp.2023.149","volume":"224","author":"O Corbeil","year":"2024","unstructured":"Corbeil O, Brodeur S, Courteau J, B\u00e9chard L, Huot-Lavoie M, Angelopoulos E, et al. Treatment with psychostimulants and atomoxetine in people with psychotic disorders: reassessing the risk of clinical deterioration in a real-world setting. Br J Psychiatry. 2024;224(3):98\u2013105.","journal-title":"Br J Psychiatry"},{"issue":"6","key":"3998_CR15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/JCP.0000000000000406","volume":"35","author":"AM Cressman","year":"2015","unstructured":"Cressman AM, Macdonald EM, Huang A, Gomes T, Paterson MJ, Kurdyak PA, et al. Prescription stimulant use and hospitalization for psychosis or mania: a population-based study. J Clin Psychopharmacol. 2015;35(6):667\u201371.","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"3998_CR16","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1176\/appi.ajp.20230329","volume":"181","author":"LV Moran","year":"2024","unstructured":"Moran LV, Skinner JP, Shinn AK, Nielsen K, Rao V, Taylor ST, et al. Risk of incident psychosis and mania with prescription amphetamines. Am J Psychiatry. 2024;181(10):901\u20139.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"3998_CR17","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJMoa1813751","volume":"380","author":"LV Moran","year":"2019","unstructured":"Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med. 2019;380(12):1128\u201338.","journal-title":"N Engl J Med"},{"issue":"1","key":"3998_CR18","doi-asserted-by":"publisher","first-page":"e300876","DOI":"10.1136\/bmjment-2023-300876","volume":"27","author":"H Jacques","year":"2024","unstructured":"Jacques H, Vanessa R, Genevi\u00e8ve D, Philippe G, Antoine Y, Agn\u00e8s S, et al. Psychosis with use of amphetamine drugs, methylphenidate and atomoxetine in adolescent and adults. BMJ Mental Health. 2024;27(1):e300876.","journal-title":"BMJ Mental Health"},{"issue":"2","key":"3998_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaacop.2024.01.003","volume":"2","author":"R Elmaghraby","year":"2024","unstructured":"Elmaghraby R, Pines A, Geske JR, Coombes BJ, Leung JG, Croarkin PE, et al. Risk of newly diagnosed psychotic symptoms in youth receiving medications for attention-deficit\/hyperactivity disorder. JAACAP Open. 2024;2(2):135\u201344.","journal-title":"JAACAP Open"},{"issue":"3","key":"3998_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/JCP.0000000000001552","volume":"42","author":"KE Gallagher","year":"2022","unstructured":"Gallagher KE, Funaro MC, Woods SW. Prescription stimulants and the risk of psychosis: a systematic review of observational studies. J Clin Psychopharmacol. 2022;42(3):308\u201314.","journal-title":"J Clin Psychopharmacol"},{"key":"3998_CR21","unstructured":"(Sundhedsstyrelsen) DHA. National clinical recommendations for Combination Therapy with Antipsychotics and ADHD Medication for Patients with Primary Psychotic Disorders. Sundhedsstyrelsen; 2024."},{"key":"3998_CR22","doi-asserted-by":"crossref","unstructured":"Coghill D, Banaschewski T, Cortese S, Asherson P, Brandeis D, Buitelaar J, et al. The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG). Eur Child Adolesc Psychiatry. 2021:1-25.","DOI":"10.1007\/s00787-021-01871-x"},{"key":"3998_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.neuroimage.2015.07.035","volume":"121","author":"ND Volkow","year":"2015","unstructured":"Volkow ND, Wang GJ, Smith L, Fowler JS, Telang F, Logan J, et al. Recovery of dopamine transporters with methamphetamine detoxification is not linked to changes in dopamine release. Neuroimage. 2015;121:20\u20138.","journal-title":"Neuroimage"},{"issue":"7","key":"3998_CR24","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register\u2013opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726\u201335.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3998_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","volume":"31","author":"JF Ludvigsson","year":"2016","unstructured":"Ludvigsson JF, Almqvist C, Bonamy A-KE, Ljung R, Micha\u00eblsson K, Neovius M, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31:125\u201336.","journal-title":"Eur J Epidemiol"},{"key":"3998_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.","journal-title":"BMC Public Health"},{"issue":"9","key":"3998_CR27","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","volume":"32","author":"HL Brooke","year":"2017","unstructured":"Brooke HL, Talback M, Hornblad J, Johansson LA, Ludvigsson JF, Druid H, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32(9):765\u201373.","journal-title":"Eur J Epidemiol"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-03998-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-03998-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-03998-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:17:13Z","timestamp":1775024233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-03998-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3998"],"URL":"https:\/\/doi.org\/10.1038\/s41398-026-03998-4","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors PB, JF, JH, HW, MG and JW report no biomedical financial interests or potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"226"}}